R. Ungaro, S. Mehandru, P. B. Allen, L. Peyrin-biroulet, J. Colombel et al., Lancet Lond Engl, vol.389, issue.16, pp.32126-32128, 2017.

J. Torres, S. Mehandru, and J. Colombel, Peyrin-Biroulet L. Crohn's disease, Lancet Lond Engl, vol.389, issue.16, pp.31711-31712, 2017.

G. Bouguen, B. G. Levesque, B. G. Feagan, A. Kavanaugh, and L. Peyrin-biroulet,

J. F. Colombel, Treat to target: a proposed new paradigm for the management of Crohnés disease, Clin Gastroenterol Hepatol, vol.13, issue.6, pp.1042-50, 2015.

L. Peyrin-biroulet, W. Sandborn, B. E. Sands, W. Reinisch, W. Bemelman et al., Selecting Therapeutic Targets in Inflammatory Bowel Disease
URL : https://hal.archives-ouvertes.fr/hal-01191653

, Determining Therapeutic Goals for Treat-to-Target, Am J Gastroenterol, vol.110, issue.9, pp.1324-1362, 2015.

G. Doherty, K. H. Katsanos, J. Burisch, M. Allez, K. Papamichael et al.,

, European Crohn's and Colitis Organisation Topical Review on Treatment Withdrawal

, Inflammatory Bowel Disease, vol.12, pp.17-31, 2018.

E. Louis, J. Y. Mary, G. Vernier-massouille, J. C. Grimaud, Y. Bouhnik et al., Maintenance of remission among patients with Crohn's disease on antimetabolite therapy after infliximab therapy is stopped, Gastroenterology, vol.142, issue.1, pp.63-70, 2012.

M. J. Casanova, M. Chaparro, V. García-sánchez, O. Nantes, E. Leo et al., Evolution After Anti-TNF Discontinuation in Patients With Inflammatory Bowel Disease: A Multicenter Long-Term Follow-Up Study, Am J Gastroenterol, vol.112, issue.1, pp.120-151, 2017.

W. J. Sandborn, B. G. Feagan, P. Rutgeerts, S. Hanauer, J. Colombel et al.,

, Vedolizumab as induction and maintenance therapy for Crohn's disease, N Engl J Med, vol.369, issue.8, pp.711-732, 2013.

B. G. Feagan, P. Rutgeerts, B. E. Sands, S. Hanauer, J. F. Colombel et al.,

B. E. Sands, B. G. Feagan, P. Rutgeerts, J. Colombel, W. J. Sandborn et al., Vedolizumab as induction and maintenance therapy for ulcerative colitis, N Engl J Med, vol.369, issue.8, pp.699-710, 2013.

, Effects of vedolizumab induction therapy for patients with Crohn's disease in whom tumor necrosis factor antagonist treatment failed, Gastroenterology, vol.147, issue.3, pp.618-627, 2014.

M. Chaparro, A. Garre, E. Ricart, M. Iborra, F. Mesonero et al., Short and long-term effectiveness and safety of vedolizumab in inflammatory bowel disease: results from the ENEIDA registry, Aliment Pharmacol Ther, vol.48, issue.8, pp.839-51, 2018.

S. Schreiber, A. Dignass, L. Peyrin-biroulet, G. Hather, D. Demuth et al.,

, Systematic review with meta-analysis: real-world effectiveness and safety of vedolizumab in patients with inflammatory bowel disease, J Gastroenterol, vol.53, issue.9, 2018.

A. Amiot, M. Serrero, L. Peyrin-biroulet, J. Filippi, B. Pariente et al.,

, Three-year effectiveness and safety of vedolizumab therapy for inflammatory bowel disease

,

, a prospective multi-centre cohort study, Aliment Pharmacol Ther, vol.50, issue.1, pp.40-53, 2019.

E. Louis, Stopping Biologics in IBD-What Is the Evidence?, Inflamm Bowel Dis, vol.24, issue.4, pp.725-756, 2018.

T. Engel, B. Ungar, D. E. Yung, S. Ben-horin, R. Eliakim et al., Vedolizumab in IBD-Lessons From Real-world Experience; A Systematic Review and Pooled Analysis, J Crohns Colitis, vol.12, issue.2, pp.245-57, 2018.

A. Amiot, J. Grimaud, L. Peyrin-biroulet, J. Filippi, B. Pariente et al.,

, Effectiveness and Safety of Vedolizumab Induction Therapy for Patients With Inflammatory Bowel Disease, Clin Gastroenterol Hepatol Off Clin Pract J Am Gastroenterol Assoc, vol.14, issue.11, 2016.

A. Amiot, M. Serrero, L. Peyrin-biroulet, J. Filippi, B. Pariente et al., Oneyear effectiveness and safety of vedolizumab therapy for inflammatory bowel disease: a prospective multicenter cohort study, press. 19. Gisbert JP, vol.111, pp.632-679, 2017.

Y. Bouhnik, M. Lémann, J. Y. Mary, G. Scemama, R. Taï et al.,

, Long-term follow-up of patients with Crohn's disease treated with azathioprine or 6-mercaptopurine, Lancet Lond Engl, vol.347, issue.8996, pp.215-224, 1996.

D. Sorrentino, P. Nash, M. Viladomiu, R. Hontecillas, and J. Bassaganya-riera, Stopping anti-TNF agents in patients with Crohn's disease in remission: is it a feasible long-term, Pharmacol Ther, vol.42, issue.4, pp.391-405, 2015.

F. Schnitzler, H. Fidder, M. Ferrante, M. Noman, I. Arijs et al., Longterm outcome of treatment with infliximab in 614 patients with Crohn's disease: results from a single-centre cohort, Gut, vol.58, issue.4, pp.492-500, 2009.

J. Colombel, R. Panaccione, P. Bossuyt, M. Lukas, F. Baert et al.,

, Effect of tight control management on Crohn's disease (CALM): a multicentre, randomised, controlled phase 3 trial, Lancet Lond Engl, vol.390, issue.17, pp.32641-32648, 2018.

N. A. Kennedy, B. Warner, E. L. Johnston, L. Flanders, P. Hendy et al.,

, Relapse after withdrawal from anti-TNF therapy for inflammatory bowel disease: an observational study, plus systematic review and meta-analysis, Aliment Pharmacol Ther, vol.43, issue.8, pp.910-933, 2016.

X. Treton, Y. Bouhnik, J. Mary, J. Colombel, B. Duclos et al.,

, Azathioprine withdrawal in patients with Crohn's disease maintained on prolonged remission: a high risk of relapse, Clin Gastroenterol Hepatol Off Clin Pract J Am Gastroenterol Assoc, vol.7, issue.1, pp.80-85, 2009.